Market Signal Briefing

2 hours ago

Tether says it will buy the controlling stake Exor has in Juventus, along with all remaining shares, an offer Exor has reportedly rebuffed.

Crypto stablecoin issuer Tether says it has launched a bid to fully acquire the Italian professional soccer club, Juventus Football Club, which has reportedly already been shot down.

Tether said on Friday that it submitted a binding all-cash proposal to Exor, the holding company of the Agnelli family, for its 65.4% controlling stake in Juventus that it has held for over 100 years.

If Exor agrees, then Tether will make a “public offer for the remaining shares at the same price.” Juventus is a public company with a market capitalization of 944.49 million euros ($1.1 billion), having closed trading on Friday up 2.3% to 2.23 euros ($2.62).

However, AFP reported that Tether’s bid has already been rebuffed, with a source close to Exor saying that “Juventus is not for sale.” Exor and Tether did not immediately respond to Cointelegraph’s request for comment.

Tether promises $1.1 billion investmentTether said it’s prepared to invest 1 billion euros ($1.1 billion) in the support and development of Juventus if the transaction completes.

“Tether is in a position of strong financial health and intends to support Juventus with stable capital and a long horizon,” said Tether CEO Paolo Ardoino.

Source: Tether“For me, Juventus has always been part of my life,” Ardoino added. “I grew up with this team. As a boy, I learned what commitment, resilience, and responsibility meant by watching Juventus face success and adversity with dignity.”

Tether, which issues the self-named stablecoin Tether (USDT), has looked to expand its business beyond the token and has taken up investing in artificial intelligence, robotics and a health platform. 

The company first bought a stake in Juventus in February and boosted its stake to over 10% in April.

It has since looked to boost its influence on the club and, in October, nominated its deputy investment chief, Zachary Lyons, along with Francesco Garino, to the football club’s board of directors.

The bids have paid off, as Juventus shareholders approved Garino’s appointment to the board of directors last month.

Magazine: Peter McCormack’s Real Bedford Football Club puts Bitcoin on the map

Bitcoin has broken from its long-standing correlation with equities, marking its first full-year divergence from stocks in over a decade.

The shift highlights a growing disconnect between crypto and traditional markets, raising questions about Bitcoin’s role in the current cycle.

Sponsored

Sponsored

A Historic Market DecouplingBitcoin and stocks have historically moved in tandem. However, that relationship appears to have fractured.

According to Bloomberg data, the S&P 500 has climbed more than 16% this year while Bitcoin is down 3%, marking the first such split since 2014.

BREAKING: Bitcoin is headed for its first full-year split from stocks in over a decade, marking the first time since 2014 equities rallied while crypto fell. pic.twitter.com/Ns25xJ2KV2

— Short Squeez (@shortsqueeznews) December 7, 2025
Such a clean break is unusual even by crypto standards, prompting renewed scrutiny of Bitcoin’s role within global markets. The divergence challenges expectations that regulatory optimism and institutional participation would automatically translate into sustained performance.

It is especially striking given the broader environment, where artificial intelligence stocks are soaring, capital spending is accelerating, and investors are pouring back into equities. At the same time, traditional defensive assets are attracting attention, suggesting investors are reallocating rather than broadly embracing risk.

Crypto-specific pressures, including forced liquidations and a sharp decline in retail participation, have materially exacerbated Bitcoin’s underperformance. Billions of unwound positions have amplified downside moves, turning what began as a correction into an industry retreat.

Sponsored

Sponsored

As these signals accumulate, market sentiment has weakened, sparking debate over whether this represents a routine correction or a more significant structural change.

Normal Pullback Or Something More?Bitcoin has long behaved as a momentum-driven asset, but the breakdown in sustained upside suggests that leadership within risk markets has shifted elsewhere.

Inflows into Bitcoin ETFs have slowed, prominent endorsements have grown quieter, and key technical indicators are flashing renewed weakness.

Price action reflects that cooling confidence. Bitcoin has struggled to regain momentum since its October peak near $126,000 and is now hovering closer to $90,000, reinforcing the sense that this divergence is being driven by fading conviction rather than short-term volatility alone.

Despite the current divergence, longer time horizons complicate the narrative. 

On a multi-year basis, Bitcoin continues to outperform equities, suggesting the recent split may reflect earlier excess gains unwinding rather than a decisive break in trend. 

From that perspective, underperformance could still align with a normal pullback within a broader bull-market cycle, despite calendar-year contrasts.

TLDR:

Table of Contents

TLDR:AMINA Bank Expands Capabilities Through Ripple PaymentsRipple Deepens Institutional Connectivity in EuropeGet 3 Free Stock Ebooks

AMINA Bank integrates Ripple Payments to bridge fiat and blockchain rails for efficient transactions.
Ripple’s partnership allows AMINA Bank clients to streamline cross-border payments using stablecoins.
Ripple’s licensed payments infrastructure supports more than $95 billion in daily volume globally.
AMINA Bank leads crypto adoption by incorporating Ripple’s end-to-end payments solution for seamless payments.

Ripple Payments has become central to a new partnership with AMINA Bank AG, enabling near real-time cross-border transactions for the Swiss institution’s global clients. 

The FINMA-regulated crypto bank is now the first European bank to activate Ripple’s licensed end-to-end payments system, strengthening both companies’ efforts to reduce friction between blockchain networks and traditional financial rails. 

The development expands their earlier engagement, which began when AMINA Bank adopted Ripple’s RLUSD for custody and trading.

Ripple confirmed the announcement on X, stating that the partnership provides a compliant link between fiat and blockchain rails for crypto-native clients seeking efficient global transactions. 

The company described the step as part of its broader commitment to secure digital asset infrastructure across established financial markets.

Big News: @AMINABankGlobal is the first European bank to go live with Ripple Payments: https://t.co/3cxySxnZeI

This partnership provides a crucial, compliant bridge between traditional fiat and blockchain rails, solving a major friction point for crypto-native clients who need…

— Ripple (@Ripple) December 12, 2025

AMINA Bank Expands Capabilities Through Ripple Payments
AMINA Bank intends to rely on Ripple Payments to streamline fund movements across borders and reduce reliance on legacy correspondent networks. 

The bank expects the system to deliver faster processing, lower operational costs, and improved transaction transparency for both fiat and stablecoin operations. This approach supports clients needing seamless settlement channels that align with regulatory standards.

Myles Harrison, Chief Product Officer at AMINA Bank, addressed the challenges faced by blockchain-driven companies, noting that “native web3 businesses often run into friction when working with legacy banking systems.” 

He added that traditional institutions have yet to fully support cross-border stablecoin transactions, creating operational constraints. According to Harrison, Ripple’s system enables AMINA Bank to “significantly increase our capability, reducing cross-border friction and helping our crypto-native clients maintain their competitive edge.”

The broader goal is to support both digital asset firms and traditional financial institutions that have started to integrate blockchain solutions. 

AMINA Bank views Ripple’s infrastructure as a tool that strengthens its role within the evolving global financial landscape.

Ripple Deepens Institutional Connectivity in Europe
Ripple stated that the partnership enables AMINA Bank to serve as an on-ramp for digital asset innovators seeking regulated access to established financial channels. 

Cassie Craddock, Managing Director for the UK and Europe at Ripple, said the collaboration creates “a crucial bridge between fiat and blockchain rails,” giving AMINA Bank’s clients access to seamless payments using RLUSD, other stablecoins, and rapid payouts in multiple currencies.

The announcement followed a tweet from Ripple confirming that AMINA Bank is the first European bank to go live with Ripple Payments. 

The company noted that its global reach now includes regulated corridors in Australia, Brazil, Dubai, Mexico, Singapore, Switzerland, and the United States.

With more than $95 billion in processed volume through Ripple Payments and coverage spanning over 90 percent of daily FX markets, the integration positions both entities for broader institutional activity in blockchain-powered payments across Europe.

Carl Erik Rinsch, known for directing the movie “47 Ronin,” was convicted of wire fraud and money laundering for misappropriating funds provided by Netflix for a science-fiction series, the U.S. Attorney’s Office in New York announced.

Summary

Hollywood director Carl Erik Rinsch was convicted of wire fraud and money laundering for misusing Netflix funds.
Prosecutors said Rinsch diverted the money into personal accounts and speculative trades—including Dogecoin—and luxury items.
Rinsch faces up to 20 years per fraud and laundering count.

Rinsch was found guilty of one count of wire fraud and one count of money laundering, each carrying a maximum sentence of 20 years in prison.

Prosecutors also secured convictions on five counts of engaging in monetary transactions in property derived from specified unlawful activity, with each count carrying a maximum sentence of 10 years. Sentencing is scheduled for April 17, 2026.

According to the indictment unsealed in Manhattan federal court on March 18, Rinsch reached an agreement with Netflix in 2018 to produce episodes of a science-fiction series. After spending the initial budget, the streaming service transferred additional funds in March 2020 to complete the project. The series was never finished, according to federal prosecutors.

Within days of receiving the additional funds, Rinsch transferred the money through multiple bank accounts and into a personal brokerage account, prosecutors said. The funds were then used to make speculative securities purchases, according to the announcement.

“His trading was unsuccessful, and within two months after receiving the additional funds, Rinsch had lost more than half of them,” the U.S. Attorney’s Office stated.

Prosecutors alleged that Rinsch spent a portion of the funds on stock options and cryptocurrency, including Dogecoin. Despite reportedly realizing a substantial profit on the Dogecoin investment, the funds were intended for production expenses, according to the indictment.

Rinsch also spent millions on luxury items, credit card bills, and additional cryptocurrency investments, prosecutors said.

Rinsch’s attorney argued that the verdict could set a precedent that would allow contractual and creative disputes between artists and financial backers to result in federal fraud charges.

Juventus' majority owners stand firm despite Tether's billion-euro offer, highlighting the club's deep-rooted ties and strategic value.

Key Takeaways

Tether has made an all-cash bid to acquire a full stake in Juventus Football Club, but the Agnelli family has stated they do not intend to sell.
Tether is offering significant investment and has become a major shareholder, leveraging its position as the issuer of the USDT stablecoin.

Tether’s bid for full control of Juventus faces strong resistance from the Agnelli family, the Italian dynasty that owns the football club, Bloomberg reported Friday, citing sources familiar with the situation.

The crypto giant announced hours ago that it had formally submitted a binding, all-cash bid to acquire a 65.4% stake in Juventus from Exor, the Agnelli family’s holding company. Juventus would secure a €1 billion investment from Tether if the deal goes through.

The club’s owner insisted there was no intention of selling after the bid became public, which aligns with previous remarks by Exor CEO John Elkann, who stated that they were not interested in a takeover but open to collaboration.

Tether is Juventus’ second-largest shareholder after earlier purchases. The company secured its first seat on the club’s board last month, becoming the first non-Agnelli-backed board member since 2001.

CEO Paolo Ardoino has made no secret of his goal to “make Juventus great again.”

“From the beginning, our goal has always been to support the team and bring it back to the glory it deserves,” he shared in a statement.

The club Ardoino grew up supporting has not posted an annual net profit in nearly a decade, and its shares have fallen about 28% this year. These factors may influence the Agnelli family’s decision.

The family has recently considered selling other underperforming assets, such as its media group Gedi.

Still, Juventus is much more central to the Agnelli family’s identity, and selling the club would be extremely controversial due to fan loyalty.

Disclaimer

Bitcoin (BTC) continues to trade within the recent consolidation phase, hovering around $90,000 at the time of writing on Friday, as investors digest the Federal Reserve’s (Fed) cautious December rate cut and its implications for risk assets. 

BTC price action approaches a key descending trendline that could determine its next directional move. Meanwhile, institutional flows into Spot Bitcoin ETFs showed mild inflows, and Strategy added more BTC to its treasury reserve.

Fed’s Policy Tone Triggers Consolidation in BitcoinBitcoin price started the week on a positive note, extending its weekend recovery during the first half of the week and holding above $92,600 on Tuesday. 

However, momentum softened on Wednesday, with BTC closing at $92,015 after the Federal Open Market Committee (FOMC) meeting. 

In a widely expected move, the Fed lowered interest rates by 25 basis points. But the FOMC meeting signaled a likely pause in January. 

Sponsored

Sponsored

Adding to the cautious tone, policymakers projected only a one-quarter-percentage-point cut for the overall 2026 outlook. This was the same outlook as in September, which tempered market expectations of two rate cuts and contributed to short-term pressure on risk assets. 

The Fed’s cautious tone, combined with disappointing Oracle earnings, contributed to a brief risk-off move. 

All these factors weighed on riskier assets, with the largest cryptocurrency by market capitalization sliding to a low of $89,260 before rebounding and finishing above $92,500 on Thursday. 

With no major US data releases ahead, crypto markets will now look to FOMC member speeches and broader risk sentiment for direction

at the end of the week. 

BTC is likely to consolidate in the near term unless a significant catalyst emerges. 

Russia-Ukraine Uncertainty Limits Risk-on Momentum On the geopolitical front, US President Donald Trump is “extremely frustrated” with Russia and Ukraine, and he doesn’t want any more talk, his spokeswoman said on Thursday. 

Earlier, Ukrainian President Volodymyr Zelenskyy said that the US was pushing the country to cede land to Russia as part of an agreement to end a nearly four-year war. 

These lingering geopolitical tensions and stalled peace talks continue to weigh on global risk sentiment, limiting risk-on appetite and contributing to Bitcoin’s consolidation so far this week. 

Institutional Demand Sees Mild Signs of Improvement Institutional demand for Bitcoin shows mild signs of improvement. 

According to SoSoValue data, US-listed spot Bitcoin ETFs recorded a total inflow of $237.44 million through Thursday, following a mild outflow of $87.77 million a week earlier, signaling that institutional investor interest improved somewhat. 

However, these weekly inflows remain small relative to those observed in mid-September. For BTC to continue its recovery, the ETF inflows should intensify. 

Total Bitcoin Spot ETF Net Inflow Chart. Source: SoSoValue Sponsored

Sponsored

On the corporate front, Strategy Inc. (MSTR) announced on Monday that it purchased 10,624 Bitcoin for $962.7 million between December 1 and 7 at an average price of $90,615. 

The firm currently holds 660,624 BTC, valued at $49.35 billion. Strategy still retains substantial capacity to raise additional capital, potentially allowing for further large-scale Bitcoin accumulation. 

On-Chain Data Shows Easing Selling Pressure CryptoQuant’s weekly report on Wednesday highlights that selling pressure on Bitcoin is beginning to ease.

The report notes that exchange deposits eased as large players reduced their transfers to exchanges. 

The graph below shows that the share of total deposits from large players has declined from a 24-hour average high of 47% in mid-November to 21% as of Wednesday. 

At the same time, the average deposit has declined by 36%, from 1.1 BTC in November 22 to 0.7 BTC. 

Bitcoin Exchange Flows. Source: CryptoQuantCryptoQuant concludes that, if selling pressure remains low, a relief rally could push Bitcoin back to $99,000. This level is the lower band of the Trader On-chain Realized Price bands, which is a price resistance during bear markets. 

After this level, the key price resistances are $102,000 (one-year moving average) and $112,000 (the Trader On-chain Realized price).

Bitcoin Trader’s Realized Price BandsThe Copper Research report also signaled optimism about Bitcoin. The report suggests that BTC’s four-year cycle hasn’t died; it has been replaced. 

Sponsored

Sponsored

Since the launch of spot ETFs, Bitcoin has exhibited repeatable Cost-Basis Return Cycles, as shown in the graph below.

Bitcoin USD Price Vs ETF Cost BasisFadi Aboualfa, Head of Research at Copper, told FXStreet that “Since spot ETFs launched, Bitcoin has moved in repeatable mini-cycles where it pulls back to its cost basis and then rebounds by around 70%. 

With BTC now trading near its $84,000 cost basis, this pattern suggests a move north of $140,000 in the next 180 days. 

If the cost basis rises 10-15%, as in prior cycles, the resulting premium seen at past peaks produces a target range of $138,000 to $148,000. 

Bitcoin Santa Rally Ahead? Bitcoin posted a 17.67% loss in November, disappointing traders who had anticipated a rally based on its strong historical returns for the month (see CoinGlass data below). 

December has historically been a positive month for the king crypto, delivering an average return of 4.55%.

Bitcoin Monthly Returns. Source: CoinGlassLooking at quarterly data, the fourth quarter (Q4) has been the best quarter for BTC in general, with an average return of 77.38%. 

Still, the performance in the last three months of 2025 has been underwhelming so far, posting for now a 19% loss.

Sponsored

Sponsored

Is BTC Setting a Bottom? Bitcoin’s weekly chart shows the price finding support around the 100-week Exponential Moving Average (EMA) at $85,809, posting two consecutive green candles following a four-week correction that began in late October. 

As of this week, BTC is trading slightly higher, holding above $92,400. 

If BTC continues its recovery, it could extend the rally toward the 50-week EMA at $99,182.

The Relative Strength Index (RSI) on the weekly chart reads 40, pointing upward and indicating fading bearish momentum. For the recovery rally to be sustained, the RSI should move above the neutral level of 50. 

BTC/USDT weekly chart On the daily chart, Bitcoin’s price was rejected at the 61.8% Fibonacci retracement level at $94,253 (drawn from the April low of $74,508 to the all-time high of $126,199 set in October) on Wednesday. 

However, on Thursday, BTC rebounded after retesting its $90,000 psychological level. 

If BTC breaks above the descending trendline (drawn by connecting multiple highs since early October) and closes above the $94,253

resistance level, it could extend the rally toward the $100,000 psychological level. 

The Relative Strength Index (RSI) on the daily chart is stable near the neutral 50 level, suggesting the lack of near-term momentum in either side. 

For the bullish momentum to be sustained, the RSI should move above the neutral level. 

Meanwhile, the Moving Average Convergence Divergence (MACD) showed a bullish crossover at the end of November, which remains intact, supporting the bullish thesis. 

BTC/USDT Daily Chart If BTC were to resume its downward correction, the first key support is at $85,569, which aligns with the 78.6% Fibonacci retracement level.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

XRP is being positioned as something more than a trading asset as analysts point to signs suggesting it may be shaped for financial infrastructure over time.

A report from Digital Asset Solutions (DAS) highlights three main points behind this shift, tying the altcoin’s technical setup to Ripple’s work on stablecoins and regulated payment rails.

Structural Edge For XRP
Reports have disclosed that XRP offers several qualities that matter to companies moving money across borders. It settles fast, costs little to send, and works as a neutral bridge asset between different currencies.

Ripple’s ledger is described as reliable and globally distributed, which is why some enterprises are testing it for predictable transfers. However, many firms still use RippleNet without using the crypto directly, so broad bank-level usage has not taken hold.

🚨 DAS Research just laid out the clearest confirmation yet of where XRP is heading

Their analysis shows XRP and Ripple are no longer competing in crypto.

They are evolving into global payment infrastructure, the kind used by banks, fintechs, and cross border networks that… pic.twitter.com/ZwqUD68Qur

— Stern Drew (@SternDrewCrypto) December 9, 2025

The research frames these features as the first major factor behind the digital asset’s potential role in global payment flows. The traits are real, but adoption varies and has not yet reached large commercial scale.

Source: DAS Research
Stablecoins And XRP Working Together
Ripple plans to use RLUSD as a fiat-backed anchor while relying on the crypto to provide liquidity between different corridors.

The concept is simple: Stablecoins maintain price stability tied to fiat, while XRP acts as the connector for moving value across currencies. This pairing is presented as the second major point in DAS Research’s findings.

Ripple Prime, ZK-enabled identity tools, and licensing efforts are being built to meet compliance requirements from regulated institutions.

XRPUSD now trading at $2.04. Chart: TradingView
Early RLUSD corridors have started to appear, but the level of real-world transaction volume remains small compared to the broader payments industry.

Catalysts Forming In The Background
The final point focuses on developments that analysts believe could help XRP move closer to regulated financial rails.

RippleNet partnerships are growing, institutional custody services are improving, RLUSD integrations are underway, and conversations around possible ETF structures have emerged.

Image: Trading News
Each of these adds some weight to the idea that XRP may gain a deeper role in payment systems in the future. Some of these steps are active today, while others remain early discussions. Custody upgrades, for example, are happening across the crypto sector, not only for the altcoin.

While procedural steps like exchange listings and filings have progressed for multiple XRP ETF proposals, the US Securities and Exchange Commission has not yet given formal approval to a spot XRP ETF. Even so, these developments show how Ripple is preparing for broader institutional use.

Featured image from Unsplash, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Christian, a journalist and editor with leadership roles in Philippine and Canadian media, is fueled by his love for writing and cryptocurrency. Off-screen, he's a cook and cinephile who's constantly intrigued by the size of the universe.

Bitcoin News

Miners Control 12% of Corporate Bitcoin Reserves

TL;DR: Publicly listed and private Bitcoin mining companies collectively hold nearly 127,000 BTC. This reserve represents 12% of the total Bitcoin held in corporate treasuries

Bitcoin News

One Miner, One Block: Solo Player Hits Bitcoin Jackpot

TL;DR A solo miner mined a full Bitcoin block and earned 3.133 BTC ($284,000) using only a few machines and ~270 TH/s. The probability of success for

CryptoCurrency News

Crypto Winter Tightens Its Grip on Bitcoin Miners as the AI Pivot Accelerates

TLDR: Bitcoin’s hash price dropped to a historic low, leaving most public miners unprofitable (breakeven point at ~$90,000). Growing unprofitability, exacerbated by the 2024 halving,

flash news

Bitcoin Technical Indicator Sparks Buy Call at $90K Level

The Bitcoin Hash Ribbons is signaling a buy as BTC hovers near $90,000. The indicator has historically proven reliable in spotting bottoms, reflecting miner pressure

flash news

JPMorgan Highlights Strategy as Key Driver in Bitcoin Forecast Despite Miner Selling

JPMorgan stated that Strategy’s strong balance sheet outweighs miner selling pressure and supports Bitcoin’s stability. The firm noted that high-cost miners have sold BTC following

Bitcoin News

Authorities in Malaysia Target Illegal Bitcoin Mining Over $1.1 Billion Power Loss

TL;DR Authorities reveal that nearly 14,000 illegal sites stole $1.1 billion in electricity since 2020. Thermal imaging drones and handheld sensors are being used to

CryptoCurrency News

$400M Crypto Liquidations Shake BTC & ETH — Reset or Risk-Off?

TL;DR: The crypto market experienced over $400 million in leveraged position liquidations in just 24 hours. Ethereum (ETH) led the losses with $180 million liquidated,

CryptoCurrency News

Crypto Market Rally: BTC Peaks While Select Altcoins Deliver Double‑Digit Returns

TL;DR Bitcoin surged $10,000 to reach $94,000, its highest price in the last two weeks. Ethereum surpassed $3,000, while SUI led the rally with an

Bitcoin News

Crypto Markets Add $130B as Bitcoin Tops $91K, Traders Eye Rally Momentum

TL;DR Bitcoin shoots up close to $92,000, recovering from its lowest point in seven months (below $81,000). The total crypto market capitalization soars, adding over

Bitcoin News

Bitcoin Price Risks Drop Below $80K as Concerns Over ‘MSTR Hit Job’ Intensify

TL;DR The price of the pioneering cryptocurrency is once again under pressure. Now, it exposes a risk of further declines as a weakened technical structure

Bitcoin News

Analysts Warn Bitcoin’s Latest Rally Could Falter With Another Drop Ahead

TL;DR The recent shakeout in the Bitcoin price provided a brief breather to the market, exiting oversold conditions evident on the 4-hour chart. The Relative

Bitcoin News

Bitcoin Faces $13.3B Options Expiry as Price Trades Below Max Pain

TL;DR A total of 153,778 BTC in options contracts, valued at $13.3 billion, expire this Friday. The “Max Pain” price is set at $102,000, indicating

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin has failed to reclaim higher prices, reinforcing the growing belief that the market may be entering a deeper bearish phase. After multiple attempts to push above key resistance levels, BTC continues to trade sideways with declining momentum, reflecting a clear shift in investor sentiment. Fear is rising across the market, and price action has yet to show any convincing signs of recovery.

According to new data shared by Axel Adler, several structural on-chain and market indicators now support a continuation of bearish conditions in the months ahead. Adler’s analysis points to weakening demand, persistent sell pressure, and deteriorating liquidity—factors that historically precede prolonged corrective periods.

While Bitcoin has held above critical support zones, its inability to establish higher highs or sustain rebounds suggests that buyers remain cautious and largely defensive.

Moreover, broader market conditions show similar fragility, with derivatives positioning, stablecoin flows, and long-term holder behavior all signaling reduced conviction. This confluence of factors strengthens the bearish thesis and implies that volatility could intensify before the market finds a meaningful bottom.

Bitcoin MVRV Spread Signals a Deep Bear Phase
Adler’s analysis highlights one of the clearest structural indicators pointing toward sustained bearish conditions: the Bitcoin MVRV Z-Score Bull vs. Bear Market model. Specifically, he notes that the 30-day to 365-day MVRV spread is deeply negative and continues to deteriorate.

This spread measures the difference in profitability between short-term and long-term holders, and when the short-term cohort is underperforming significantly, it traditionally signals risk aversion, exhaustion, and weakening demand.

Bitcoin MVRV Z-Score Bull vs Bear Market | Source: Axel Adler
A crossover—when the 30-day MVRV rises above the 365-day metric—has historically marked the transition from bear markets into new bullish phases. However, Adler stresses that such a crossover does not appear imminent under current conditions. The spread remains far below the threshold required for a structural reversal, reinforcing the view that Bitcoin is still entrenched in a deep bear phase within this model’s framework.

Cycle analogs further support this interpretation. Reviewing past market cycles, Adler estimates that the next likely window for a meaningful crossover sits in the second half of 2026. This implies that even if short-term rallies occur, they are more likely to be counter-trend bounces rather than the early stages of a sustainable bull market. Until the MVRV structure improves, broader sentiment may remain decisively bearish.

Price Struggles to Recover Momentum
Bitcoin continues to move sideways, reflecting a market that remains indecisive and structurally weak. The chart shows BTC trading near $92,000 after its sharp decline from the $120,000 region, with recent candles forming a tight consolidation range. This behavior typically signals a temporary stabilization phase rather than a confirmed reversal, especially given the broader bearish context highlighted by on-chain and macro indicators.

BTC consolidates below $95K | Source: BTCUSDT chart on TradingView
The 50-day moving average sits well above the current price, acting as dynamic resistance and indicating that short-term momentum remains firmly bearish. Likewise, the 100-day and 200-day moving averages trend downward, creating a compression zone that BTC has yet to challenge. Until Bitcoin can reclaim these levels with conviction, rallies may continue to be faded by sellers.

Despite the small rebound from sub-$90,000 levels, buying activity remains muted compared to the heavy sell volume that drove the initial breakdown. This suggests that demand is insufficient to absorb higher-timeframe selling pressure.

Structurally, Bitcoin is forming lower highs and lower lows across the daily timeframe, reinforcing a downtrend. A decisive break below $90,000 would expose deeper liquidity zones near $86,000–$84,000. Conversely, reclaiming $96,000 would be the first sign of strength—but current price action shows no such momentum yet.

Featured image from ChatGPT, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Sebastian's journey into the world of crypto began four years ago, driven by a fascination with the potential of blockchain technology to revolutionize financial systems. His initial exploration focused on understanding the intricacies of various crypto projects, particularly those focused on building innovative financial solutions. Through countless hours of research and learning, Sebastian developed a deep understanding of the underlying technologies, market dynamics, and potential applications of cryptocurrencies.
As his knowledge grew, Sebastian felt compelled to share his insights with others. He began actively contributing to online discussions on platforms like X and LinkedIn, focusing on fintech and crypto-related content. His goal was to expose valuable trends and insights to a wider audience, fostering a deeper understanding of the rapidly evolving crypto landscape. Sebastian's contributions quickly gained recognition, and he became a trusted voice in the online crypto community.
To further enhance his expertise, Sebastian pursued a UC Berkeley Fintech: Frameworks, Applications, and Strategies certification. This rigorous program equipped him with valuable skills and knowledge regarding Financial Technology, bridging the gap between traditional finance (TradFi) and decentralized finance (DeFi). The certification deepened his understanding of the broader financial landscape and its intersection with blockchain technology.
Sebastian's passion for finance and writing is evident in his work. He enjoys delving into financial research, analyzing market trends, and exploring the latest developments in the crypto space. In his spare time, Sebastian can often be found immersed in charts, studying 10-K forms, or engaging in thought-provoking discussions about the future of finance.
Sebastian's journey as a crypto analyst and investor has been marked by a relentless pursuit of knowledge and a dedication to sharing his insights. His ability to navigate the complex world of crypto, combined with his passion for financial research and communication, makes him a valuable asset to the industry. As the crypto landscape continues to evolve, Sebastian remains at the forefront, providing valuable insights and contributing to the growth of this revolutionary technology.

Journalist

Posted: December 13, 2025

Derivatives data from CoinGlass shows that more than $17.17 million worth of Sui [SUI] was withdrawn from exchanges over the past week, signaling strong accumulation. 

This trend suggests that current conditions may present an attractive buying opportunity.

What is the key level in SUI?
The major liquidation map shows that traders are currently focusing on $1.512 as the lower level and $1.694 as the upper level.

Bullish sentiment around SUI is heating up, boosted by its recent inclusion in the Bitwise 10 Crypto Index ETF (BITW), ongoing accumulation, rising bullish bets from traders, and the broader market recovery.

At press time, the altcoin was trading at $1.64, up 6.35%, while market participation has dropped compared to the previous day.

According to data from crypto price tracker CoinMarketCap, SUI’s 24-hour trading volume has declined by 22% to $831 million.

Despite the price rise, the drop in trading volume indicates that market participants are exercising caution amid broader market trends and ongoing volatility.

SUI’s inclusion in Bitwise’s BITW ETF
The main driver of SUI’s recent surge is its addition to the Bitwise 10 Crypto Index ETF (BITW), which started trading on the NYSE Aeca on the 10th of December 2025.

BITW’s latest update shows a 0.24% allocation to SUI, equal to $2.4 million at launch, creating fresh demand for the token.

Strong traders and investors demand
Another factor driving SUI’s upside momentum is the combination of massive accumulation and heavy long‑position bets, as shown on the derivatives platform CoinGlass.

According to CoinGlass, traders are leaning strongly toward long positions. The market was over‑leveraged, at the time of writing, with $1.512 marked as the lower level and $1.694 as the upper level.

At these price points, traders have built $17.63 million in long leveraged positions compared to $5.72 million in short positions. This imbalance highlights strong intraday bullish sentiment and reinforces confidence in the ongoing rally.

Source: CoinGlass

In addition to trader activity, long‑term holders are showing confidence in the asset. CoinGlass’s SUI Spot Inflow/Outflow metric reveals that, over the past week, about $17.17 million worth of SUI has left exchanges.

This outflow, as of press time, points to potential accumulation.

Source: CoinGlass

SUI price action and upcoming levels
AMBCrypto’s technical analysis on the daily chart shows that SUI’s recent gains have brought it back to a key support level of $1.60.

Based on current price action and historical patterns, if the altcoin maintains its upward momentum and closes a daily candle above $1.75, it could see another price jump of 26%, potentially reaching $2.20.

Source: TradingView

At press time, SUI’s Average Directional Index (ADX) stood at 26.68, above the key threshold of 25, indicating strong directional momentum.

Final Thoughts

SUI’s strong accumulation, ETF inclusion, and bullish positioning highlight growing confidence despite cautious trading volume.
A daily close above $1.75 could trigger a 26% rally, targeting the $2.20 resistance zone.

Vivaan Acharya is a Crypto-Economist and Journalist at AMBCrypto who brings a rare depth of financial and economic expertise to the world of digital assets. He holds a Master’s in Economics from the prestigious University of Delhi and has over five years of experience analyzing technology and financial markets.
His foray into the blockchain space began in 2018, marked by his prescient Master's thesis, "Payments and Stablecoin Integration in Banking," which showcased his early understanding of crypto's potential to disrupt traditional finance. Before specializing in crypto, Vivaan honed his skills in rigorous data and technical chart analysis at a major national financial daily, where he covered corporate earnings and market trends.
At AMBCrypto, Vivaan applies this powerful blend of classical economic training and seasoned financial journalism to his work. He is an expert in:
1. Bitcoin and Altcoin Market Analysis
2. Stablecoin Ecosystem Development, and
3 Emerging Crypto Regulations.
Known for his clear, no-nonsense approach, Vivaan translates robust research into straightforward, actionable insights. He is dedicated to demystifying the complexities of blockchain finance, empowering readers to confidently navigate the rapidly evolving digital economy.

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC

, /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by previously available therapies.2

"There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the mutation," said Bradley McGregor, M.D., Director of Clinical Research for the Lank Center of Genitourinary Oncology at Dana-Farber Cancer Institute. "AMPLITUDE is the first study to show that this precision medicine combination of a PARP inhibitor with an androgen receptor pathway inhibitor delays both radiographic and symptomatic disease progression."

The approval is based on positive results from AMPLITUDE (NCT04497844), a randomized, double-blind, placebo-controlled, international Phase 3 clinical study. In patients with BRCA2-mutated mCSPC, treatment with AKEEGA® plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54 percent (hazard ratio [HR] 0.46; 95 percent confidence interval [CI], 0.32–0.66) compared to placebo/abiraterone acetate plus prednisone and ADT, which is the current standard of care.1 AKEEGA® plus prednisone and ADT also significantly prolonged the time to symptomatic progression by 59 percent (HR 0.41; 95 percent CI, 0.29–0.65).1

The observed safety profile of the combination of AKEEGA® plus prednisone was consistent with the known safety profile of each FDA-approved monotherapy. In the AMPLITUDE clinical study, the most common adverse reactions (≥20%) including laboratory abnormalities, were decreased hemoglobin, decreased lymphocytes, musculoskeletal pain, fatigue, decreased platelets, increased alkaline phosphatase, constipation, hypertension, nausea, decreased neutrophils, increased creatinine, increased potassium, decreased potassium, decreased aspartate aminotransferase, fluid retention/edema, increased bilirubin, respiratory tract infection and arrhythmia.1  

"This expanded indication for AKEEGA reflects our commitment to push the boundaries of science and deliver more personalized, effective treatment options across the prostate cancer continuum," said Mahadi Baig, M.D., M.H.C.M., Vice President, Head of Solid Tumors, U.S. Medical Affairs, Johnson & Johnson Innovative Medicine. "Supported by strong clinical data, AKEEGA is now the first and only PARP-based precision medicine combination treatment in BRCA2-mutated mCSPC, offering patients hope for more time with a new way to potentially delay their cancer from progressing."

Johnson & Johnson is committed to helping patients access our treatments. Once a patient and their doctor have decided that AKEEGA® is right for the patient, J&J withMe provides a simple, comprehensive patient support program offering cost support and educational resources, at no cost to the patient.

*The hazard ratio [HR] 0.46; 95 percent confidence interval [CI], 0.32–0.66) compared to standard of care, AKEEGA® plus prednisone and ADT also significantly prolonged the time to symptomatic progression by 59 percent (HR 0.41; 95 percent CI, 0.29–0.65).1 

About AMPLITUDE
AMPLITUDE (NCT04497844) is an ongoing, Phase 3, randomized, double-blind, placebo-controlled, multicenter, global study evaluating the efficacy and safety of niraparib and abiraterone acetate in a dual-action tablet (DAT) formulation with prednisone plus androgen deprivation therapy (ADT) compared to matching oral placebo/abiraterone acetate with prednisone plus ADT in patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The primary endpoint is radiographic progression-free survival (rPFS). The study enrolled 696 participants from 32 countries.

About Metastatic Castration-Sensitive Prostate Cancer
Metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC), refers to prostate cancer that has spread to other parts of the body but still responds to hormone therapy (androgen deprivation therapy).3 While the treatment landscape has advanced in recent years, almost all patients eventually develop resistance to therapy, and the disease progresses to metastatic castration-resistant prostate cancer (mCRPC) – an aggressive and currently incurable disease stage.4 Approximately 25 percent of patients with mCSPC have HRR gene alterations, including BRCA, which have been shown to negatively impact outcomes.2,5 Patients with BRCA mutations experience approximately 50 percent faster disease progression and shorter survival, representing a significant unmet medical need not addressed by previously available therapies.2 

About AKEEGA® (niraparib and abiraterone acetate)
AKEEGA® is a dual-action tablet (DAT), combining niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor. AKEEGA® together with prednisone or prednisolone was approved in April 2023 by the European Medicines Agency, and in August 2023 by the U.S. FDA following Priority Review, for the treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). AKEEGA® plus prednisone was approved by the U.S. FDA in December 2025 under Priority Review for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Patients are selected for therapy based on an FDA-approved test for genetic alterations. Additional marketing authorization applications are under review across a number of countries globally.

In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GlaxoSmithKline [GSK] in 2019) for exclusive rights to niraparib in prostate cancer.

For more information visit www.akeegahcp.com. 

AKEEGA® INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

AKEEGA® is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with:

deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC).
deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
Select patients for therapy based on an FDA approved test for AKEEGA®

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Myelodysplastic Syndrome/Acute Myeloid Leukemia
AKEEGA® may cause myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).

In the individual AMPLITUDE and MAGNITUDE studies, MDS or AML, including cases with fatal outcomes, were reported in 0.6% (2/347) and 0.5% (1/212) of patients treated with AKEEGA® plus prednisone, respectively.

All patients in other tumor types treated with niraparib, a component of AKEEGA®, who developed secondary MDS/cancer-therapy-related AML had received previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.

For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation. Discontinue AKEEGA® if MDS/AML is confirmed.

Myelosuppression
AKEEGA® may cause myelosuppression (anemia, thrombocytopenia, or neutropenia).

In AMPLITUDE, Grade 3-4 anemia, neutropenia, and thrombocytopenia were reported, respectively in 29 %, 10 %, and 4.9% of patients receiving AKEEGA®. Overall, 25% of patients with anemia required a red blood cell transfusion, including 15% who required more than one transfusion. Discontinuation due to anemia occurred in 1.2% of patients.

In MAGNITUDE Cohort 1, Grade 3-4 anemia, thrombocytopenia, and neutropenia were reported, respectively in 28%, 8%, and 7% of patients receiving AKEEGA®. Overall, 27% of patients with anemia required a red blood cell transfusion, including 19.5% who required more than one transfusion. Discontinuation due to anemia occurred in 3% of patients.

Monitor complete blood counts weekly during the first month of AKEEGA® treatment, every two weeks for the next two months, monthly for the remainder of the first year and then every other month, and as clinically indicated. Do not start AKEEGA® until patients have adequately recovered from hematologic toxicity caused by previous therapy. If hematologic toxicities do not resolve within 28 days following interruption, discontinue AKEEGA® and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.

Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions
AKEEGA® may cause hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. In post-marketing experience, QT prolongation and Torsades de Pointes have been observed in patients who develop hypokalemia while taking abiraterone acetate, a component of AKEEGA®.  Hypertension and hypertensive crisis have also been reported in patients treated with niraparib, a component of AKEEGA®.

In AMPLITUDE, which used prednisone 5 mg daily in combination with AKEEGA®, Grades 3-4 hypokalemia was detected in 9% of patients on the AKEEGA® arm, and Grades 3-4 hypertension was observed in 30% of patients on the AKEEGA® arm.

In MAGNITUDE Cohort 1, which used prednisone 10 mg daily in combination with AKEEGA®, Grades 3-4 hypokalemia was detected in 2.7% of patients on the AKEEGA® arm and Grades 3-4 hypertension was observed in 14% of patients on the AKEEGA® arm.

Monitor patients for hypertension, hypokalemia, and fluid retention at least weekly for the first two months, then once a month. Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia, or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. Control hypertension and correct hypokalemia before and during treatment with AKEEGA®. Discontinue AKEEGA® in patients who develop hypertensive crisis or other severe cardiovascular adverse reactions.

The safety of AKEEGA® in patients with New York Heart Association (NYHA) Class II to IV heart failure has not been established because these patients were excluded from AMPLITUDE and MAGNITUDE.

Hepatotoxicity
AKEEGA® may cause hepatotoxicity.

Hepatotoxicity in patients receiving abiraterone acetate, a component of AKEEGA®, has been reported in clinical trials. In post-marketing experience, there have been abiraterone acetate-associated severe hepatic toxicity, including fulminant hepatitis, acute liver failure, and deaths.

In AMPLITUDE, Grade 3-4 ALT or AST increases (at least 5x ULN) were reported in 1.9% and 1.3% of patients, respectively.

In MAGNITUDE Cohort 1, Grade 3-4 ALT or AST increases (at least 5x ULN) were reported in 1.8% and 0.9% of patients respectively.

The safety of AKEEGA in patients with moderate or severe hepatic impairment has not been established as these patients were excluded from AMPLITUDE and MAGNITUDE.

Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment with AKEEGA®, every two weeks for the first three months of treatment and monthly thereafter. Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs suggestive of hepatotoxicity develop.  Elevations of AST, ALT, or bilirubin from the patient's baseline should prompt more frequent monitoring and may require dosage modifications.

Permanently discontinue AKEEGA® for patients who develop a concurrent elevation of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation, or in patients who develop ALT or AST ≥20 x ULN at any time after receiving AKEEGA®.

Adrenocortical Insufficiency
AKEEGA® may cause adrenal insufficiency.

Adrenocortical insufficiency has been reported in clinical trials in patients receiving abiraterone acetate, a component of AKEEGA®, in combination with prednisone, following interruption of daily steroids and/or with concurrent infection or stress. Monitor patients for symptoms and signs of adrenocortical insufficiency, particularly if patients are withdrawn from prednisone, have prednisone dose reductions, or experience unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with abiraterone acetate. If clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical insufficiency. Increased doses of corticosteroids may be indicated before, during, and after stressful situations.

Hypoglycemia
AKEEGA® may cause hypoglycemia in patients being treated with other medications for diabetes.

Severe hypoglycemia has been reported when abiraterone acetate, a component of AKEEGA®, was administered to patients receiving medications containing thiazolidinediones (including pioglitazone) or repaglinide.

Monitor blood glucose in patients with diabetes during and after discontinuation of treatment with AKEEGA®. Assess if antidiabetic drug dosage needs to be adjusted to minimize the risk of hypoglycemia.

Increased Fractures and Mortality in Combination with Radium 223 Dichloride
AKEEGA® with prednisone is not recommended for use in combination with Ra-223 dichloride outside of clinical trials.

The clinical efficacy and safety of concurrent initiation of abiraterone acetate plus prednisone/prednisolone and radium Ra 223 dichloride was assessed in a randomized, placebo-controlled multicenter study (ERA-223 trial) in 806 patients with asymptomatic or mildly symptomatic castration-resistant prostate cancer with bone metastases. The study was unblinded early based on an Independent Data Monitoring Committee recommendation.

At the primary analysis, increased incidences of fractures (29% vs 11%) and deaths (39% vs 36%) have been observed in patients who received abiraterone acetate plus prednisone/prednisolone in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus prednisone.

It is recommended that subsequent treatment with Ra-223 not be initiated for at least five days after the last administration of AKEEGA®, in combination with prednisone.

Posterior Reversible Encephalopathy Syndrome
AKEEGA® may cause Posterior Reversible Encephalopathy Syndrome (PRES).
PRES has been observed in patients treated with niraparib as a single agent at higher than the recommended dose of niraparib included in AKEEGA®.

Monitor all patients treated with AKEEGA® for signs and symptoms of PRES. If PRES is suspected, promptly discontinue AKEEGA® and administer appropriate treatment. The safety of reinitiating AKEEGA® in patients previously experiencing PRES is not known.

Embryo-Fetal Toxicity
The safety and efficacy of AKEEGA® have not been established in females. Based on animal reproductive studies and mechanism of action, AKEEGA® can cause fetal harm and loss of pregnancy when administered to a pregnant female.

Niraparib has the potential to cause teratogenicity and/or embryo-fetal death since niraparib is genotoxic and targets actively dividing cells in animals and patients (e.g., bone marrow).

In animal reproduction studies, oral administration of abiraterone acetate to pregnant rats during organogenesis caused adverse developmental effects at maternal exposures approximately ≥ 0.03 times the human exposure (AUC) at the recommended dose.

Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of AKEEGA®. Females who are or may become pregnant should handle AKEEGA® with protection, e.g., gloves.

ADVERSE REACTIONS
BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Serious adverse reactions occurred in 36% of patients who received AKEEGA®. Serious adverse reactions reported in >2% of patients included anemia (4.9%), and pneumonia (3.7%). Fatal adverse reactions occurred in 4.9% of patients who received AKEEGA®, including sudden death (1. 9%), COVID-19 pneumonia (1.2%), pneumocystis jirovecii pneumonia (0.6%), pneumonia (0.6%), and cardio-respiratory arrest (0.6%).

The most common adverse reactions (>20%), including laboratory abnormalities, in patients who received AKEEGA® were decreased hemoglobin, decreased lymphocyte count, hypertension, decreased neutrophil count, musculoskeletal pain, decreased platelet count, constipation, fatigue, decreased potassium, increase creatinine, nausea, increased alkaline phosphate, increased aspartate aminotransferase, respiratory tract infection, arrhythmia, increased blood bilirubin, and fluid retention/edema.

BRCA-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Serious adverse reactions occurred in 41% of patients who received AKEEGA®. Serious adverse reactions reported in >2% of patients included COVID-19 (7%), anemia (4.4%), pneumonia (3.5%), and hemorrhage (3.5%). Fatal adverse reactions occurred in 9% of patients who received AKEEGA®, including COVID-19 (5%), cardiopulmonary arrest (1%), dyspnea (1%), pneumonia (1%), and septic shock (1%).

The most common adverse reactions (>20%), including laboratory abnormalities, in patients who received AKEEGA® were hemoglobin decreased, lymphocyte decreased, musculoskeletal pain, fatigue, platelets decreased, constipation, alkaline phosphatase increased, hypertension, nausea, neutrophils decreased, creatinine increased, potassium increased, potassium decreased, and aspartate aminotransferase increased.

DRUG INTERACTIONS

Effect of Other Drugs on AKEEGA®
Avoid coadministration with strong CYP3A4 inducers.
Abiraterone is a substrate of CYP3A4. Strong CYP3A4 inducers may decrease abiraterone concentrations, which may reduce the effectiveness of abiraterone.

Effects of AKEEGA® on Other Drugs
CYP2D6 Substrates
Avoid coadministration unless otherwise recommended in the Prescribing Information for CYP2D6 substrates for which minimal changes in concentration may lead to serious toxicities. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug.

Abiraterone is a CYP2D6 moderate inhibitor. AKEEGA® increases the concentration of CYP2D6 substrates, which may increase the risk of adverse reactions related to these substrates.

CYP2C8 Substrates
Monitor patients for signs of toxicity related to a CYP2C8 substrate for which a minimal change in plasma concentration may lead to serious or life-threatening adverse reactions.

Abiraterone is a CYP2C8 inhibitor. AKEEGA® increases the concentration of CYP2C8 substrates, which may increase the risk of adverse reactions related to these substrates.

USE IN SPECIFIC POPULATIONS

Geriatric Use

Of the 162 patients with BRCA2 gene alteration(s) who received AKEEGA® in AMPLITUDE, 40% of patients were less than 65 years, 36% of patients were 65 years to 74 years, and 23% were 75 years and over.

Of the 113 patients with BRCA gene alteration(s) who received AKEEGA® in MAGNITUDE, 34.5% of patients were less than 65 years, 38.9% of patients were 65 years to 74 years, and 26.5% were 75 years and over.

No overall differences in effectiveness were observed between patients 65 years of age or older and younger patients in AMPLITUDE or MAGNITUDE. Patients 75 years of age or older who received AKEEGA® experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was 4.3% in patients younger than 75 and 13% in patients 75 or older.

Hepatic Impairment

Avoid use in patients with moderate or severe hepatic impairment. No dosage modification is necessary for patients with mild hepatic impairment.

Renal Impairment

Monitor patients with severe renal impairment for increased adverse reactions and modify dosage as recommended for adverse reactions. No dosage modification is recommended for patients with mild to moderate renal impairment.

Please see the full Prescribing Information for AKEEGA®.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of AKEEGA®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

1 AKEEGA® U.S. Prescribing Information.

2 Olmos D, Lorente D, Jambrina A, et al. BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 2025;36(10):1190-1202. doi:10.1016/j.annonc.2025.05.534

3 National Cancer Institute. Hormone-sensitive prostate cancer. Accessed December 2025. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hormone-sensitive-prostate-cancer

4 Narayan V, et al. Treatment patterns and survival outcomes among androgen receptor pathway inhibitor-experienced patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2024;22(6):1-14. doi:10.1016/j.clgc.2024.102188

5 Gonzalez D, Mateo J, Stenzinger A, et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J Pathol Clin Res. 2021;7(4):311-325. doi:10.1002/cjp2.203

SOURCE Johnson & Johnson

You can find higher yields in the energy patch, but it is hard to find businesses as reliable as these two conservatively run industry giants.

High-yield stocks have to be treated with caution. If you just buy the highest-yielding investments you can find, you are likely to be let down. The key is to find a balance between risk and reward, which is what you'll achieve by investing in Enterprise Products Partners (EPD 0.25%) and Enbridge (ENB +0.29%). Here's why these are no-brainer high-yield energy stocks today.

The energy sector is vital and volatile
The modern world can't function without energy, which is why most investors should have some exposure to the energy sector in their portfolios. However, the energy sector also tends to be highly volatile, due to the fluctuating prices of energy commodities such as oil and natural gas. This top-level view, however, doesn't tell the whole story.

Image source: Getty Images.

The energy sector is generally broken down into three parts: the upstream, the midstream, and the downstream. The upstream is where oil and natural gas are produced. The downstream is where oil and natural gas are processed into usable products. Both are commodity-driven and volatile. The midstream, by contrast, is a toll-taker business that connects the upstream to the downstream and the rest of the world. The volume flowing through a company's pipelines and other energy infrastructure is what's most important in the midstream, not the price of the commodities being used.

Even during deep energy market downturns, demand for oil and natural gas tends to remain robust. This is why even conservative dividend investors can be comfortable investing in the midstream if they are looking to add some energy exposure to their portfolios. However, not all midstream businesses are equally reliable, and examining yield alone is insufficient to determine whether an investment is worth owning.

Buy Enterprise and Enbridge
If all you did was look at yield, you might buy a midstream player like Energy Transfer (ET +0.91%). Its 7.9% yield is far higher than the 6.7% yield you'd collect from Enterprise Products Partners or the 5.7% dividend yield on offer from Enbridge. In fact, Energy Transfer's business isn't a bad one, but its history as an income stock is lacking. In 2020, the distribution was halved.

Today's Change

(

-0.25

%) $

-0.08

Current Price

$

32.13

In fairness, 2020's cut occurred during the midst of the coronavirus pandemic. It was a highly uncertain time for the world and for energy markets. The decision helped to solidify the balance sheet and set Energy Transfer up well to survive both that period and future periods of uncertainty. However, it also set a precedent that investors looking to live off the income their portfolios generate shouldn't ignore. Enterprise and Enbridge both increased their shareholder payments in 2020.

Enterprise has now increased its distribution for 27 consecutive years. Enbridge's streak is up to 30 years. What you are giving up in yield, you are making up for in proven consistency. For most long-term dividend investors, that will be a worthwhile trade-off.

Today's Change

(

0.29

%) $

0.14

Current Price

$

47.55

Enterprise is particularly attractive today because it has been increasingly focusing on natural gas. Natural gas is expected to serve as a transitional fuel as the world moves toward cleaner energy alternatives, such as renewable power. Add in an investment-grade rated balance sheet and the fact that distributable cash flow covers the distribution by a comfortable 1.7x, and even the most conservative of dividend investors will find it attractive.

Despite having a lower yield, Enbridge could gain an edge over Enterprise for some investors. That's because Enbridge's portfolio includes oil pipelines, natural gas pipelines, regulated natural gas utilities, and clean energy investments. The regulated natural gas utilities it owns have fairly consistent growth prospects, while the clean energy investments show it is already changing its business along with the world's energy needs. The diversification outside of the energy sector could make this Canadian midstream giant the right choice for ultra-conservative dividend lovers.

Look past the yield when looking at energy stocks
Investors seeking yield might find Energy Transfer attractive, but there are trust issues that more conservative investors shouldn't ignore. The yield alone won't explain why those concerns are important, but a quick look at the history of the business (notably that 2020 distribution cut) will.

A more attractive risk-reward ratio awaits dividend investors who take a closer look at their income options. That's when lower-yielding, but more reliable investment options, such as Enterprise and Enbridge, start to jump out. If you are focused on energy, Enterprise will probably be the better choice for you. If you're looking for a clean energy hedge, Enbridge should probably be your choice.

Q3: 2025-12-11 Earnings SummaryEPS of -$0.10 beats by $0.15

 |

Revenue of

$184.17M

beats by $8.12M

Netskope, Inc. (NTSK) Q3 2026 Earnings Call December 11, 2025 5:00 PM EST

Company Participants

Michelle Spolver - Chief Communications & Investor Relations Officer
Sanjay Beri - Co-Founder, CEO & Chairman
Andrew Del Matto - Chief Financial Officer

Conference Call Participants

Meta Marshall - Morgan Stanley, Research Division
Brian Essex - JPMorgan Chase & Co, Research Division
Matthew Hedberg - RBC Capital Markets, Research Division
Shaul Eyal - TD Cowen, Research Division
Brad Zelnick - Deutsche Bank AG, Research Division
Robbie Owens - Piper Sandler & Co., Research Division
Ittai Kidron - Oppenheimer & Co. Inc., Research Division
Trevor Walsh - Citizens JMP Securities, LLC, Research Division
Gregg Moskowitz - Mizuho Securities USA LLC, Research Division
Eric Heath - KeyBanc Capital Markets Inc., Research Division
Shrenik Kothari - Robert W. Baird & Co. Incorporated, Research Division
Gray Powell - BTIG, LLC, Research Division

Presentation

Operator

And thank you for standing by. Welcome to Netskope Third Quarter Fiscal 2026 Earnings Conference Call. [Operator Instructions]

I'd now like to hand the conference over to Michelle Spolver, Chief Communications and Investor Relations Officer. You may begin.

Michelle Spolver
Chief Communications & Investor Relations Officer

Good afternoon, and thank you for joining us today. With me on the call are Netskope's CEO and Co-Founder, Sanjay Beri; and CFO, Drew Del Matto. The press release announcing our financial results for the third quarter of fiscal year 2026 was issued earlier today and is posted to our Investor Relations website at investors.netskope.com, along with a supplemental presentation.

Before we begin, let me remind everyone that some of the statements we make on today's call are forward-looking, including statements related to our guidance for the fourth quarter and full 2026 fiscal year, growth opportunities and competitive position. These forward-looking statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those anticipated by these statements. Additionally, these

Recommended For You

, /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Integer holdings Corporation (NYSE: ITGR) securities between July 25, 2024 and October 22, 2025. Integer is a leading global medical device contract manufacturer specializing in cardiac rhythm management and cardiovascular products.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Integer Holdings Corporation (ITGR) Misled Investors Regarding Demand for its Products

According to the complaint, the action alleges that defendants misled investors regarding the Company's market position in the growing EP ("electrophysiology") market and vastly overstated demand for Integer's EP devices. In reality, demand for Integer's EP devices had fallen off a cliff. Indeed, rather than the Company's EP business outpacing market growth in the burgeoning EP market, revenue growth from Integer's EP devices was in fact decelerating.

On October 23, 2025, Integer cut its full-year 2025 guidance and informed investors it expected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026. Integer further admitted that two of its EP devices had experienced "slower than forecasted" market adoption and expected the slower demand impact "to continue into 2026." On this news, Integer common stock fell $35.22 per share, or more than 32%, to close at $73.89 per share on October 23, 2025.

What Now: You may be eligible to participate in the class action against Integer Holdings Corporation. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by February 9, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. 

To be notified if a class action against Integer Holdings Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

SOURCE Robbins LLP

NEW YORK , Dec. 12, 2025 /PRNewswire/ -- Scully Royalty Ltd. (the "Company") (NYSE: SRL) provided today an update with respect to its annual general meeting (the "Meeting") currently scheduled for December 27, 2025, following the filing by MILFAM LLC ("MILFAM") of a purported dissident proxy circular on December 8, 2025 to nominate five individuals to the Company's board of directors.

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.

'Mad Money' host Jim Cramer takes a deep dive into RH.

The S&P 500 reached a new record high this week, crossing the 6,900 milestone for the first time ever. However, the index experienced its largest daily loss in three weeks on Friday, ultimately leading to a weekly loss of 0.6%. Here is a snapshot of the index from the past week:

The table below summarizes the number of record highs reached each year dating back to 2013.

Here is a snapshot of the index from the past six months with a 50-day moving average:

S&P 500: A Perspective on Drawdowns
On October 9, 2007 the S&P 500 reached a then all-time high, closing the day at 1565.15. Then on March 9, 2009, the index dropped ~57% off of its high from exactly 17 months before, closing the day at 676.53. This time period became known as the Global Financial Crisis. It took over 5 years before the index reached a new then all-time high on March 28, 2013, where it closed out at 1569.19. The chart below is a snapshot of record highs and selloffs since the 2007 peak reached on October 9, 2007.

What happens if we take out the Global Financial Crisis? Here’s a snapshot the same chart above where the start date has been changed to the trough reached on March 9, 2009. Note the recent selloffs in 2022.

Here are a few tables with the number of days of a 1% or greater change in either direction and the number of days of corrections (down 10% or more from the record high).

 

And here is a linear chart of the index since October 9, 2007:

Here is a linearly scaled version of the same chart with the 50- and 200-day moving averages. The index has been above the 50-day moving average since November 24th and above the 200-day moving average since May 12th. Additionally the 50-day moving average has been above the 200-day moving average since July 1st.

S&P 500: A Perspective on Volatility
For a sense of the correlation between the closing price and intraday volatility, the chart below overlays the S&P 500 since 2007 with the intraday price range. On April 9th, the index experienced its largest intraday price volatility (10.77%) since December 24th, 2018 (19.10%). Also included is the 20-day moving average to identify trends in volatility. Over the past 20 days, the average percent change from the intraday low to the intraday high is 1.25%.

S&P 500 versus S&P Equal Weight
The S&P 500 is market cap-weighted index which includes roughly the 500 largest U.S. stocks spanning 11 sectors. The S&P 500 Equal Weight Index includes the same constituents as the S&P 500 but each company is equally weighted at a fixed weight. So how do these two indexes match up against each other this year?

The S&P 500 is currently up 16.34% year to date, while the S&P Equal Weight is up 10.42% year to date.

ETFs associated with the S&P 500 include: iShares Core S&P 500 ETF (IVV), SPDR S&P 500 ETF Trust (SPY), Vanguard S&P 500 ETF (VOO), SPDR Portfolio S&P 500 ETF (SPYM), and Invesco S&P 500® Equal Weight ETF (RSP).

Originally published on Advisor Perspectives

For more news, information, and strategy, visit the Fixed Income Content Hub.

Earn free CE credits and discover new strategies

December 12, 2025 7:33 PM EST | Source: Lode Gold Resources Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - Lode Gold Resources Inc (TSXV: LOD) (the "Company" or "Lode Gold") is pleased to announce it has appointed David Swetlow as Chief Financial Officer ("CFO"). David is CFO of the Company's subsidiary 1475039 B.C. Ltd. ("Gold Orogen"), created to spin off its Yukon and New Brunswick mining property assets to unlock shareholder value, which is nearing the completion of "going public" via a reverse take-over ("RTO") transaction with Great Republic Mining.

The record date (the "Record Date") for determining the Lode Gold shareholders who are entitled to receive shares of Spin Co, Lode Gold's subsidiary 1475039 B.C. Ltd ("Gold Orogen" or "OROG") will be set shortly. For each one common share of Lode Gold held by a Lode Gold shareholder on or before the Record Date, a tax-free distribution of approximately 0.57 shares of Gold Orogen will be received.

David has previously held various senior management, board, and advisory roles. With over 30 years in finance, operations, strategic alliances, public company management, and corporate governance, his past extensive experience includes company formation; financing; go public; uplisting; spin-out; corporate transactions; and restructuring. His focus has been start-up, scale-up, and growth-stage companies, including Canadian and US-listed public firms, driving high value projects and innovative technology. Formally educated as a CPA ( CA), David has served as CFO, Director, Audit & Risk Committee Chair/Member, and Finance Chair for various organizations, and holds iGP governance certification and a SFU Beedie School of Business degree.

Wendy T. Chan, CEO and Director of the Company, "David was brought in a few months ago to help get Gold Orogen's spin out as a public company over the finish line. In a short time, David has demonstrated strong financial acumen, strategic, public markets and governance savvy. His skills and capabilities will nicely complement and strengthen the existing Lode Gold team."

Lode Gold has awarded Mr. Swetlow 322,000 stock options to purchase common shares of the Company at an exercise price of $0.21. The stock options are granted pursuant to the Company's 10% rolling stock option plan with 50% of the options vesting on grant and the remaining 50% vesting on the first anniversary of grant. The options expire five years from the date of issue.

About Lode Gold

Lode Gold has key assets in Canada and United States.

Fremont Gold Project (Fremont Gold Mining LLC) is a brownfield project in Mariposa, California with 43,000 m drilled, 8,000 channel samples, 14 adits and 2 shafts. Mining halted in 1942 due to the gold mining prohibition during WW II. It was mined at 10.7 g/t when price was gold was $35 per oz. PEA was completed (link) in 2023. The PEA was based on 1M oz (M&I) and 2M (Inferred). MRE (link) was updated in 2025; 92% of the ounces were left unmined. Average true widths at 1g/t cut off is 53m. Project sits on > 3,000 acres of 100% owned private and patented land which is designated as OZ, Trump Administration Opportunity Zone (Special Tax Incentives).

Gold Orogen (1475039 B.C. Ltd) is an early-stage exploration pure play with quality assets in the Yukon and New Brunswick, Canada. Optionality exists as assets are diversified on two mineral belts that are known to have prolific gold endowment.

A 19.9% strategic partner was brought in and a joint venture was formed to create one of the largest land packages in New Brunswick with mineral rights spanning 445km2.

The New Brunswick assets, McIntyre Brook and Riley Brook sit on a highly prospective belt that has seen many exciting discoveries including Dalradian, New Found Gold and Calibre Mining. Kinross- Puma surrounds McIntyre Brook.

In the Yukon, Golden Culvert/WIN sits on the southern end of the Tombstone Belt which in recent years has seen extensive exploration success. It has Reduced Intrusion (RIRGS) targets and sedimentary hosted orogenic mineralization. Over 4,500 m has been drilled with 50 gram meter intercepts.

The completion of Gold Orogen's spin out into a public company via an RTO is imminent, presenting a unique and compelling opportunity to unlock shareholder value as two standalone public companies with clear trajectory for growth will be created.

Dingman Property is an orogenic deposit in Ontario, Canada with over 22,000 m drilled, with a 2013 PEA, MRE (link to report) : 376,000 oz (M&I) and 47,000 oz (Inferred).

Qualified Person

The technical information contained in this press release was reviewed and approved by Gary Wong, P.Eng., Vice President Exploration of Lode Gold Resources Inc., designated as a Qualified Person under National Instrument 43-101.

ON BEHALF OF THE COMPANY

Wendy T. Chan
CEO & Director

Cautionary Statement Regarding Forward-Looking Information
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes "forward-looking statements" and "forward-looking information" within the meaning of Canadian securities legislation. All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the use of proceeds, advancement and completion of resource calculation, feasibility studies, and exploration plans and targets. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as "anticipate", "believe", "plan", "estimate", "expect", "potential", "target", "budget" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions and includes the negatives thereof.

Forward-looking statements are based on a number of assumptions and estimates that, while considered reasonable by management based on the business and markets in which the Company operates, are inherently subject to significant operational, economic, and competitive uncertainties, risks and contingencies. These include assumptions regarding, among other things: the status of community relations and the security situation on site; general business and economic conditions; the availability of additional exploration and mineral project financing; the supply and demand for, inventories of, and the level and volatility of the prices of metals; relationships with strategic partners; the timing and receipt of governmental permits and approvals; the timing and receipt of community and landowner approvals; changes in regulations; political factors; the accuracy of the Company's interpretation of drill results; the geology, grade and continuity of the Company's mineral deposits; the availability of equipment, skilled labour and services needed for the exploration and development of mineral properties; and currency fluctuations.

There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include a deterioration of security on site or actions by the local community that inhibits access and/or the ability to productively work on site, actual exploration results, interpretation of metallurgical characteristics of the mineralization, changes in project parameters as plans continue to be refined, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, uninsured risks, regulatory changes, delays or inability to receive required approvals, business disruptions, and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators, including those described under the heading "Risks and Uncertainties" in the Company's most recently filed MD&A. The Company does not undertake to update or revise any forward-looking statements, except in accordance with applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277976

Investors saw much to like in the company's recent performance.

Furniture retailer RH (RH +5.63%) finished the stock trading week in style, with its equity rising by nearly 6% on Friday after it reported third-quarter earnings. This, despite a bottom-line miss and several guidance cuts.

A restorative quarter
For the quarter, RH's net revenue rose by 9% year-over-year to $884 million. Net income according to generally accepted accounting principles (GAAP) also saw an increase, advancing 4% to $36.3 million. On a per-share basis, however, non-GAAP (adjusted) profitability fell to $1.71 from the year-ago figure of $2.48.

Image source: Getty Images.

The company slightly beat the average analyst estimate of under $883.3 million for revenue, but missed that for adjusted net income ($2.16 per share).

In a combined shareholder letter and earnings release, RH quoted CEO Gary Friedman as saying that "While a meaningful portion of our market share gains are coming from the fragmented to-the-trade design showrooms, regional high-end furniture stores, and local independent boutiques, we are also gaining share from the better furniture-based national brands."

RH provided a table showing that RH's third-quarter revenue performance compared favorably to a clutch of competitors that included Wayfair (up 8%), Williams-Sonoma-owned West Elm (up 4%), and Ethan Allen Interiors (down 5%).

Today's Change

(

5.63

%) $

8.63

Current Price

$

161.94

A few changes in guidance
RH made several adjustments to its full-year guidance for 2025. It now expects to post revenue growth of 9% to 9.2% in 2024, compared to a previous range of 9% to 11%. The adjusted operating margin is expected to be 11.6% to 11.9%, down from the preceding 13% to 14%. However, it left unchanged its forecast for free cash flow, which it expects to be $250 million to $300 million.

None of this greatly impresses me personally. Still, I think it's admirable that the company's revenue growth remains quite healthy, given the affordability concerns of the U.S. consumer these days and the disruptions caused by tariffs earlier this year. This isn't a bad stock for believers in the furniture retail sector.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Williams-Sonoma. The Motley Fool recommends RH and Wayfair. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Ardent Health, Inc. (NYSE: ARDT) focused on whether Ardent Health and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in the Ardent Health investigation or if you are an Ardent Health investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-ardent-health-inc-investigation-ardt.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

THE COMPANY: Ardent Health is a provider of healthcare in growing midsize urban communities across the United States. On July 18, 2024, Ardent Health raised $192 million in its initial public offering, selling 12 million shares of its common stock for $16 per share.

THE REVELATION: On November 12, 2025, Ardent Health announced its third quarter 2025 earnings, revealing that it had missed consensus estimates due in large part "payor denials [that] were more pronounced" and "an adjustment of $54 million attributable to the emergence of adverse prior period claim developments with respect to recent settlements and ongoing litigation arising from a limited set of claims between 2019 and 2022 in New Mexico for a single provider who the Company no longer employs, as well as consideration of broader industry trends, including social inflationary pressures." Regarding the payor shortfall, CFO Alfred Lumsdaine further announced that Ardent Health had implemented a "change in accounting estimate" that required Ardent Health to "recognize[] reserves earlier in an account's life cycle." As a result, Ardent Health reduced revenue in the quarter by $43 million.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

Also from this source

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Gorodenkoff / Shutterstock.com

Artificial intelligence has been the hottest industry, and its scorching success may continue for the rest of the decade. Big tech companies have spent so much money on AI that it’s impacting GDP more than consumer spending, and each of those giants has committed to more AI spending in 2026.

Following the money and seeing where the AI investments flow can result in tremendous returns for patient investors. Many AI stocks have doubled this year, with some AI stocks rallying by more than 1,000% over the past decade. 

Getting first dibs on AI stocks right now can lead to significant returns that outperform the S&P 500 by a wide margin. These are three of the top AI stocks to monitor. 

IREN (IREN)
IREN (NASDAQ:IREN) is transitioning from a crypto miner to an AI data center provider that has signed deals with big tech companies. Its highest profile deal is a 5-year, $9.7 billion agreement with Microsoft (NASDAQ:MSFT) for 200 megawatts in one of IREN’s AI data centers. The company should have 3.2 gigawatts ready to go by the end of 2027, which means it can pull off 16 more deals like the Microsoft one. That doesn’t include the multi-gigawatt development pipeline IREN told investors about in its Q1 FY26 earnings presentation.

IREN’s ability to create AI data centers and accumulate energy at scale makes it a desirable partner. While AI chips were the previous bottleneck, energy and AI data centers are the new chokepoints for AI innovation. 

The emerging AI leader expects $3.4 billion in annual recurring revenue by the end of 2026. This figure includes the Microsoft deal, but it also suggests that at least one more multi-billion dollar big tech deal will arrive next year. 

Marvell Technology (MRVL)
Every investor wants their AI chipmaker to be the next Nvidia (NASDAQ:NVDA), but a comparison with Broadcom (NASDAQ:AVGO) is more appropriate for Marvell Technology (NASDAQ:MRVL). Marvell Technology produces custom-made AI chips that are starting to gain momentum, and it’s the same business model that helped Broadcom reach a $1 trillion market cap.

Marvell Technology only trades at a 34.6 P/E ratio and has an $84 billion market cap. The company produces Amazon’s Trainium2 AI chips, which became a multi-billion dollar business segment for Amazon. The online marketplace leader also said that its AI chips grew by 1 50% quarter over quarter in its Q3 earnings report. That translates into more sales for Marvell Technology, which can cause the AI stock to double in 2026.

Marvell Technology delivered vibrant Q3 FY26 results, which featured 40% year-over-year revenue growth on “strong demand for [its] data center products.” The company also acquired Celestial AI to strengthen its position in AI data center infrastructure. It’s one of the few AI chip stocks that hasn’t had much momentum. It’s actually down by 13% this year despite doubling from its 2025 lows. However, next year might be the one where Marvell Technology gets to shine.

Cipher Mining (CIFR)
Cipher Mining (NASDAQ:CIFR) offers a similar premise to IREN. It’s a crypto miner that pivoted to AI infrastructure to sign lucrative deals with big tech companies. Cipher Mining enjoys the same catalysts as IREN and has signed multiple deals with tech giants. 

CIFR stock’s market cap is roughly $8 billion, which makes it easier for this AI stock to double than a multi-trillion dollar pick like Nvidia. Cipher Mining has deals with Amazon (NASDAQ:AMZN) and Google-backed Fluidstack and has a 3.2 gigawatt pipeline.

The company’s smaller market cap and ability to sign multi-year deals suggest that high returns are possible. Investors who view energy and AI data centers as the big bottlenecks may benefit from looking into IREN and CIFR instead of picking one over the other. 

December 12, 2025 7:51 PM EST | Source: NervGen Pharma Corp.
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that closed on July 13, 2022. The proposed amendment solely changes the denomination of the exercise price of the 2022 Warrants from US$1.75 to the Canadian equivalent of C$2.44 to align with the Company's functional currency and simplify the accounting treatment thereof. All other terms and conditions of the 2022 Warrants remain unchanged. The amended 2022 Warrant terms remain subject to acceptance by the TSX Venture Exchange.

About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first- and potential best-in-class therapeutic peptide enabling the nervous system to repair itself. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent variant of NVG-291, in animal models of spinal cord injury. These studies implicated multiple potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA and Orphan Designation from the EMA for NVG-291 in individuals with spinal cord injury.

About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. The Company is evaluating the clinical efficacy of its first- and potential best-in-class lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study in spinal cord injury. For more information about NervGen, visit www.nervgen.com and follow NervGen on X and LinkedIn for the latest news on the company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note and Forward Looking-Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the intention of the Company to proceed with the Warrant amendments and the Company receiving TSX-V approval of such amendments. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: that we will receive the necessary regulatory approvals for Warrant amendments; its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company's actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at www.sedarplus.ca. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277979

OKLAHOMA CITY--(BUSINESS WIRE)--As the leader of the No. 1 defense in the country, Ohio State University's Caleb Downs has been named the 2025 Paycom Jim Thorpe Award Winner. The announcement was made live tonight on The Home Depot College Football Awards on ESPN. Downs received the 2025 honor – given to the top defensive back in college football based on performance on the field, athletic ability and character – on behalf of the Oklahoma Sports Hall of Fame, Jim Thorpe Association and presenti.